NEW YORK , Oct. 7, 2024 /PRNewswire/ -- Report on how AI is driving market transformation - The Global Pharmaceutical Contract Research and Manufacturing Market size is estimated to grow by USD 141.3 billion from 2024-2028, according to Technavio.
The market is estimated to grow at a CAGR of 10.87% during the forecast period. Availability of cost-efficient resources in emerging markets is driving market growth, with a trend towards increasing number of US FDA approved manufacturing facilities.
However, stereotypical nature of CMOS poses a challenge - Key market players include Almac Group Ltd., Boehringer Ingelheim International GmbH, Cadila Pharmaceuticals Ltd., Catalent Inc.
, Charles River Laboratories International Inc., Cmic Holdings Co. Ltd, Dr Reddys Laboratories Ltd.
, ICON plc, IQVIA Holdings Inc., Laboratory Corp. Of America Holdings, Lonza Group Ltd.
, Lupin Ltd., Novotech Health Holdings, OPTIMAPHARM d.o.
o., Parexel International Corp., PCI Pharma Services, Recipharm AB, Samsung Electronics Co.
Ltd., Syneos Health Inc., and Thermo Fisher Scientific Inc.
. Key insights into market evolution with AI-powered analysis. Explore trends, segmentation, and growth drivers- View the snapshot of this report Market Driver The Pharmaceutical Contract Research and Manufacturing (CRAM) market is experiencing significant growth due to the increasing number of US FDA-approved manufacturing facilities in emerging economies, particularly China and India .
India , with around 400 such fa.